c-myc is critical to proliferation, growth, and apoptosis ( 1 -5 ) . Shut off of c-myc is required for differentiation and senescence. MYC interacts with the general transcription machinery, a variety of transcription factors, and with chromatin-modifying and -remodeling complexes ( 1 ) . As many as 10% of genes are MYC targets ( 6 -9 ) . Although usually an activator, some genes are also repressed by MYC. MYC is rarely a dominating force; MYC adjusts the expression of most targets by small or even incremental amounts. c-myc expression is deregulated in most cancers ( 1 , 4 , 5 , 10 ) by chromosomal translocation, viral insertions, amplification, deletions, insertions, and/or mutation of cis -elements. MYC-coding mutations occur but are not obligatory for carcinogenesis; inappropriate expression of the wild-type protein suffices.
The best characterized chromosomal pathology deregulating c-myc occurs in Burkitt lymphoma ( 1 ) . Burkitt translocations inevitably approximate c-myc on chromosome 8 with immunoglobulin (Ig) sequences from the , , or heavy-chain genes on chromosomes 2, 22, or 14, respectively. Some translocations occur within the body of the gene, but others occur hundreds of thousands of bases upstream or downstream of the major transcription start sites. Despite the juxtaposition with Ig regulatory sequences, overall c-myc expression within many tumors remains within the normal range ( 11 , 12 ) . The derangement of c-myc in these cases may disturb the timing of expression or may lead to heterogeneous levels where elevated MYC in some cells is offset by reduced expression in others.
A series of mice with declining MYC expressed from its natural locus become progressively smaller ( 13 ) . Cells making more MYC induce apoptosis in their neighbors even when the expression differential is slight ( 14 , 15 ) . Such observations reveal the importance of uniform MYC levels throughout a developmental fi eld. Whereas normal diploid human fi broblasts are immortalized by telomerase, cells haploinsuffi cient for c-myc are resistant to telomerase overexpression ( 16 ) . So expressing MYC at the proper levels, times, and locations is very important.
c-myc mRNA and protein are short lived (approximately 20 -30 minutes, each) and rare ( 1 -5 ). Usually, c-myc is expressed at low levels, as low as one transcript per cell. Resting fi broblasts contain just 500 molecules of MYC protein, rising to 5000 upon activation ( 17 ) . In embryonic tissues, myc mRNA levels have been estimated to be fi ve per cell ( 18 ) . Tumor cells express a much broader range of c-myc RNA and protein than normal cells. The instability of MYC protein and RNA together with small numbers of mRNA would seem to compel stochastic variation between cells ( 19 ) . If such fl uctuations are deleterious to normal physiology and homeostasis, mechanisms must exist to precisely control and safeguard c-myc expression. Though MYC levels are also controlled posttranscriptionally, our focus is on how the c-myc promoter works.
c-myc is transcribed from promoters, P1 and P2, separated by 150 bp. Most transcripts initiate at P2. When translocations displace P1 and P2 in Burkitt lymphomas, transcription starts at cryptic sites within intron I ( 1 -5 ). c-myc and Drosophila hsp70 were the fi rst genes shown to harbor promoter-paused RNA polymerase II (pol II) ( 20 , 21 ) . In vitro, pol II, either alone or in complex with general transcription factors, enters elongation upon the addition of the ninth nucleotide ( 22 ) . In vivo, pausing at c-myc and hsp70 promoters continues beyond +9, so either the reaction pathway is different (less probable) or some superimposed mechanism delays promoter escape (more probable). A variety of multi-subunit complexes remain associated with pol II from preinitiation complex (PIC) formation to initiation to promoter escape to elongation ( 23 , 24 ) . Because its promoter is almost always loaded, the crucial step in c-myc activation is mobilization of the paused polymerase, not the PIC assembly.
How the c-myc Promoter Works and Why It Sometimes Does Not

David Levens
The c-myc promoter is regulated by scores of signals, transcription factors, and chromatin components. The logic integrating these multiple signals remains unexplored. Recent evidence suggests that activated MYC expression is regulated in several phases: 1) conventional transcription factors trigger transcription by the RNA polymerase II (pol II) paused within the proximal promoter region. Concurrently (and probably consequently), newly arrived chromatin-remodeling complexes mobilize a nucleosome masking the far upstream element (FUSE), 1.7-kb upstream of the P2 start site; 2) binding by FUSE-binding proteins (first FBP3, then FBP); and 3) FBP-interacting repressor (FIR) binds FUSE and returns transcription to basal or steady-state levels. The recruitment and release of the FBPs and FIR is governed by FUSE-DNA conformation, itself controlled by dynamic supercoils propagated behind pol II. The organization and operation of the c-myc promoter make it difficult to inactivate, but sensitive to disturbances (translocations, viral insertions, amplification, and mutation) that disrupt the fine-tuning seen at its normal chromosomal context. ). The insights gleaned from these studies (selected fi ndings are summarized in Box 1; references were omitted because of space constraints) have greatly enhanced our understanding of 1) the assembly of the transcription complex at the c -myc promoter, transcription initiation, and promoter escape; 2) the mechanism that limits the noise at low-level c -myc expression: prepromoter escape transitions that involve TFIIH, activators of TFIIH (such as FUSE-binding proteins [FBPs] ), and repressors of TFIIH (such as FIR); 3) the underlying reason why the c-myc promoter executes a stereotypical pulse of expression peaking 2 -3 hours poststimulation followed by either shutoff and return to G0 or decline to an intermediate steady-state level of gene expression if the cell reenters the active cell cycle; 4) the role of single-stranded DNA, mechanical (torsional) stress, and supercoils at the c -myc promoter; and 5) the utilization of conventional transcription factors for an "ignition system" of the c-myc promoter that subsequently turns control over to a "servomechanism" of c-myc expression. The reader is referred to the primary literature for details.
No reporter gene, transfection system (transient, stable, or episomal), or transgenic mouse has yet been devised that faithfully recapitulates the physiological responses of the c-myc promoter to its many activating signals ( 1 -3 ). Either important cis -elements are missing or there are context-dependent requirements for c-myc transcription that can only be maintained at the normal locus. Nonetheless, the principles extracted from experimental model systems of c-myc expression have been helpful to understand the transcriptional regulation of the endogenous, normal c -myc gene, which, in turn, is a precondition for appreciating the mechanism that deregulates c -myc in the context of a chromosomal translocation, in which the panel of cis -elements that recruit factors to the c -myc promoter would be profoundly altered and promoter output would be reprogrammed. There has been much progress, but we have a long way to go before the regulation of normal and rearranged c -myc can be fully understood.
